Skip to main content

Table 1 Baseline clinical characteristics of patients

From: A randomized controlled trial of long-acting muscarinic antagonist and long-acting β2 agonist fixed-dose combinations in patients with chronic obstructive pulmonary disease

N

75

IC (L)

1.91 ± 0.51

Male:female

69:6

FVC (L)

2.81 ± 0.72

Age (years)

77.4 ± 6.9 (53–91)

FEV1 (L)

1.42 ± 0.54

Height (cm)

164.0 ± 7.2

FEV1/FVC (%)

50.5 ± 13.5

Body weight (kg)

59.3 ± 9.8

MMF (L/s)

0.56 ± 0.35

BMI (kg/m2)

22.0 ± 3.0

PF (L/s)

4.37 ± 1.72

Smoking (pack year)

Former: 71

V50 (L/s)

0.71 ± 0.47

Current: 4

V25 (L/s)

0.25 ± 0.14

52.6 ± 26.8

V50/V25

2.87 ± 1.06

PIF (L/min)

Adaptor-free

195.1 ± 62.3

Post-BD FEV1 (L)

1.46 ± 0.54

H/H

42.4 ± 7.4

%post-BD FEV1 (%)

58.8 ± 21.7

Asthma

8

Severity of airflow obstruction (grade)

I: 14

II: 36

III: 16

IV: 9

  1. BMI, body mass index; PIF, peak inspiratory flow, H/H, adaptor for handihaler; IC, inspiratory capacity; FVC, forced vital capacity; FEV1, forced expiratory volume in one second; MMF, maximal mid-expiratory flow; PF, peak expiratory flow; V50, forced expiratory flow at 50% of FVC; V25, forced expiratory flow at 25% of FVC; BD, bronchodilator